Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Prostatic Neoplasms 9Breast Neoplasms 7Neoplasms 4Lymphoma 4Brain Neoplasms 4Lymphoma, Non-Hodgkin 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Lymphoma, B-Cell 2Liver Neoplasms 2Leukemia 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Papillomavirus Infections 1Pancreatic Neoplasms 1Osteomyelitis 1Neurofibromatosis 1 1

Interventions

Pemetrexed 12Cisplatin 11pembrolizumab 8Carboplatin 6Ipilimumab 5Nivolumab 4LMB-100 4durvalumab 3Gemcitabine 3tremelimumab 2tazemetostat 2anetumab ravtansine 2Vinorelbine 2Plicamycin 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2vandetanib 1tocilizumab 1spartalizumab 1ribociclib 1rebastinib 1pevonedistat 1olaparib 1niraparib 1nintedanib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mesothelioma × Magnetic Resonance Imaging × Clear all
NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled 14 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡